918 related articles for article (PubMed ID: 29909914)
21. The acceleration of CAR-T therapy in non-Hodgkin lymphoma.
Munshi PN; Ujjani C
Hematol Oncol; 2019 Aug; 37(3):233-239. PubMed ID: 30427551
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
[TBL] [Abstract][Full Text] [Related]
23. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
24. Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.
Zhong N; Ma Q; Gong S; Shi Y; Zhao L; Wang D; Zhou H; Liu N; Ye Y; Wang J; Liu L; Guo Z
Int Immunopharmacol; 2024 Jun; 134():112174. PubMed ID: 38703571
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
Schuster SJ; Svoboda J; Chong EA; Nasta SD; Mato AR; Anak Ö; Brogdon JL; Pruteanu-Malinici I; Bhoj V; Landsburg D; Wasik M; Levine BL; Lacey SF; Melenhorst JJ; Porter DL; June CH
N Engl J Med; 2017 Dec; 377(26):2545-2554. PubMed ID: 29226764
[TBL] [Abstract][Full Text] [Related]
26. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
27. CD19-directed CAR T-cell therapy in B-cell NHL.
Kersten MJ; Spanjaart AM; Thieblemont C
Curr Opin Oncol; 2020 Sep; 32(5):408-417. PubMed ID: 32740094
[TBL] [Abstract][Full Text] [Related]
28. Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.
Jin Z; Xiang R; Qing K; Li D; Liu Z; Li X; Zhu H; Zhang Y; Wang L; Xue K; Liu H; Xu Z; Wang Y; Li J
Cell Oncol (Dordr); 2023 Aug; 46(4):1143-1157. PubMed ID: 37219767
[TBL] [Abstract][Full Text] [Related]
29. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
30. Clinical predictors of chimeric antigen receptor T-cell therapy neurotoxicity: a single-center study.
Yuen C; Rezania K; Kelly T; Bishop MR
Immunotherapy; 2021 Oct; 13(15):1261-1269. PubMed ID: 34558978
[TBL] [Abstract][Full Text] [Related]
31. Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
Zhang Y; Wang Y; Liu Y; Tong C; Wang C; Guo Y; Ti D; Yang Q; Qiao S; Wu Z; Han W
Leukemia; 2022 Jan; 36(1):189-196. PubMed ID: 34272481
[TBL] [Abstract][Full Text] [Related]
32. How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells.
Nagler A; Perriello VM; Falini L; Falini B
Br J Haematol; 2023 May; 201(3):396-410. PubMed ID: 36916189
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Ghobadi A
Curr Res Transl Med; 2018 May; 66(2):43-49. PubMed ID: 29655961
[TBL] [Abstract][Full Text] [Related]
35. Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients.
Martín-Martín L; Gutiérrez-Herrero S; Herrero-García M; Martín García-Sancho A; Yeguas A; Martín-López AÁ; López-Corral L; Pérez-López E; García-Blázquez M; Sánchez-Guijo F; Vidriales MB; Gaipa G; ; ; Orfao A
Blood Cancer J; 2024 May; 14(1):83. PubMed ID: 38760376
[No Abstract] [Full Text] [Related]
36. CAR T-cell therapy in refractory large B-cell lymphoma.
Stirrups R
Lancet Oncol; 2018 Jan; 19(1):e19. PubMed ID: 29249304
[No Abstract] [Full Text] [Related]
37. Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.
Mihăilă RG
Recent Pat Anticancer Drug Discov; 2019; 14(4):312-323. PubMed ID: 31642414
[TBL] [Abstract][Full Text] [Related]
38. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma.
Ravi D; Sarkar S; Purvey S; Passero F; Beheshti A; Chen Y; Mokhtar M; David K; Konry T; Evens AM
Leukemia; 2020 May; 34(5):1291-1304. PubMed ID: 31772298
[TBL] [Abstract][Full Text] [Related]
39. Optimization of canine CD20 chimeric antigen receptor T cell manufacturing and in vitro cytotoxic activity against B-cell lymphoma.
Sakai O; Igase M; Mizuno T
Vet Comp Oncol; 2020 Dec; 18(4):739-752. PubMed ID: 32329214
[TBL] [Abstract][Full Text] [Related]
40. A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off.
Leroy M; Deramoudt L; Pinturaud M; Demaret J; Alidjinou EK; Nudel M; Cavalieri D; Chahla WA; Odou P; Morschhauser F; Yakoub-Agha I; Simon N; Beauvais D
Leuk Lymphoma; 2024 Jun; 65(6):868-871. PubMed ID: 38440954
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
